Copyright © Inderes 2011 - present. All rights reserved.

Xbrane Biopharma

5.92 SEK

-4.42 %

Less than 1K followers

XBRANE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-4.42 %
-43.61 %
-41.95 %
-33.48 %
-82.91 %
-69.83 %
-99.50 %
-99.59 %
-98.76 %

Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.

Read more
Market cap
122M SEK
Turnover
380.88K SEK
Revenue
152.35M
EBIT %
-18.54 %
P/E
74.01
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5/5
2026

Interim report Q1'26

5/5
2026

General meeting '26

17/7
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Quite a struggle. A trainwreck, as they would say across the pond. Once again, additional information must be provided to the FDA, and the BLA has been withdrawn. An additional delay of approximately 6–12 months is expected AND even more capital may potentially be needed. For fun...
4/23/2024, 7:25 AM
by vesuri
7
xbrane.com » Xbrane and STADA partner with Valorum Biologics to commercialize... XBRANE AND STADA PARTNER WITH VALORUM BIOLOGICS TO COMMERCIALIZE RANIBIZUMAB BIOSIMILAR CANDIDATE IN THE US Based on this, could one think that obtaining FDA approval looks quite promising?
5/10/2024, 7:13 AM
by OSAKEURPO
4
Xbrane warns that it will be insolvent in a couple of months if the desired financing solutions are not reached and the company does not manage to out-license the Xdivane™ and/or XB003 candidates by the end of October. As communicated on 1 August 2024 and given the previously communicated...
8/12/2024, 11:38 AM
by vesuri
3
It’s frustrating when the reverse split isn’t properly taken into account. But that company’s journey is still not amounting to anything.
10/22/2025, 12:03 PM
by Clark kent
1
It’s hard to see any profitable future for this Ximluci. From what I’ve researched, off-label Bevacizumab is still cheaper, and on the other hand, aflibercept and faricimab are better and longer-acting. There simply isn’t a market niche.
5/10/2024, 7:34 AM
by Clark kent
1
The share price has started to wake up in recent days. Apparently in anticipation of FDA approval in April.
4/8/2024, 3:07 PM
by OSAKEURPO
1
I haven’t really followed this, but big gainers and losers are always interesting. So, a 343Mkr rights issue is being proposed for a company whose market cap fell 75% today (at the time of writing) to a market cap of 57Mkr. The rights issue will only take place after the Extraordinary...
1/22/2024, 1:46 PM
by Expaco_b
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.